Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Last trade$0.6133
Day change-$0.0077 (-1.24%)
Day range$0.586 – $0.625
Volume515,884
Market cap$245M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$244.77M
Price / earnings
1.84×
Price / book
0.44×
Price / sales
2.9×
EV / sales
-0.27×
EV / EBITDA
0.53×
Profitability
Earnings per share
$0.34
Return on assets
20.95%
Return on equity
23.95%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.75×
Quick ratio
9.4×
Cash ratio
5.24×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$65.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LAB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$19.39M
$20.1M
$21.15M
$23.8M
$19.55M
$21.76M
$20.22M
$24.78M
Cost of revenue
$8.56M
$9.57M
$9.84M
$12.41M
$10.07M
$11.13M
$9.17M
$13.42M
Gross profit
$10.83M
$10.54M
$11.31M
$11.38M
$9.48M
$10.63M
$11.05M
$11.36M
Selling, general and administrative
$16.84M
$16.39M
$18.61M
$25.34M
$26.6M
$28.11M
$29.82M
$27.32M
Research and development
$2.08M
$1.98M
$2.12M
$7.97M
$6.36M
$6.22M
$5.44M
$7.04M
Total operating expenses
$30.6M
$35.92M
$23.8M
$36.03M
$42.42M
$36.33M
$38.02M
$37.44M
Operating income
-$19.77M
-$25.39M
-$12.5M
-$24.64M
-$32.94M
-$25.7M
-$26.97M
-$26.08M
Interest expense
$0
$0
$0
-$5K
$0
$0
$0
-$572K
Income before taxes
-$14.95M
-$21.44M
-$14.62M
-$22.03M
-$32.9M
-$18.28M
-$23.49M
-$26.9M
Income taxes
$27K
$90K
$11K
-$35.93M
-$1.22M
-$609K
-$119K
$272K
Net income
$13.48M
-$26.76M
$127.07M
$19.28M
-$34.69M
-$33.46M
-$26.03M
-$34.07M
Net income attributable to common shareholders
$13.48M
-$26.76M
$127.07M
$19.28M
-$34.69M
-$33.46M
-$26.03M
-$34.07M
EBITDA
-$6.89M
-$6.56M
-$8.01M
-$20.63M
-$21.95M
-$19.71M
-$20.04M
-$19.05M
Basic earnings per share
$0.03
-$0.07
$0.33
$0.05
-$0.09
-$0.09
-$0.07
-$0.09
Diluted earnings per share
$0.03
-$0.07
$0.33
$0.05
-$0.09
-$0.09
-$0.07
-$0.09
Recent news
Company coverage with links to the original publishers.
Monteverde & Associates PC is investigating four merger transactions to determine if shareholders are receiving fair value. The investigations cover Iridium Communications' sale to Rocket Lab, VerifyMe's merger with Open World Ltd, Valaris' sale to Transocean Ltd, and Standard Biotools' merger with Treeline Biosciences. The firm is offering free consultations to shareholders with concerns about these deals.
Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.
Standard BioTools (NASDAQ:LAB) and Treeline Biosciences announced a definitive merger agreement to combine in an all-stock transaction. The combined company will operate as Treeline Biosciences under ticker 'TRLN' and will be led by Treeline CEO Josh Bilenker. The merger is expected to close in the second half of 2026, with the combined entity having over $900 million in cash runway into 2029. Standard BioTools stockholders will own approximately 16% of the combined company, while Treeline stockholders will own approximately 84%. Standard BioTools will divest its Mass Cytometry and Microfluidics businesses to maximize shareholder value.
Standard BioTools Inc. (NASDAQ: LAB) announced it will publish its first quarter 2026 financial results on Tuesday, May 5, 2026, after U.S. market close. The company is a leading provider of mass cytometry and microfluidics technologies for biomedical research.
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on February 24, 2026. The company also completed the sale of SomaLogic to Illumina for $350 million upfront with up to $425 million in total proceeds, leaving the company with approximately $550 million in cash and cash equivalents.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.